Theravance Biopharma Inc (TBPH)

Several significant events impacted Theravance Biopharma's stock price in the past six months. In Q2 2025, the company reported strong financial results with increased YUPELRI sales and completed the sale of their TRELEGY ELLIPTA royalty interest. In Q3 2025, record-high YUPELRI sales were announced, and the open-label portion of the Phase 3 CYPRESS study for ampreloxetine was completed. The Phase 3 CYPRESS study for ampreloxetine did not meet its primary endpoint, leading to the program's termination, organizational restructuring, and a strategic review. Despite the Ampreloxetine setback, the company reported record YUPELRI brand profitability for Q4 and full-year 2025, triggering milestone payments.

Based on available public information, there is no explicit mention of significant demand seasonality for Theravance Biopharma's products and services. Sales growth for YUPELRI in various quarters does not inherently suggest strong seasonal fluctuations.

Theravance Biopharma, Inc. is a biopharmaceutical company focused on discovering, researching, developing, and commercializing organ-selective medicines. The company operates in the Healthcare sector, specifically in the Pharmaceuticals industry, with a mission to deliver "Medicines that Make a Difference®". Its research is focused on inflammation, immunology, and serious respiratory and neurologic conditions. Major products include YUPELRI® (revefenacin) inhalation solution for COPD and Ampreloxetine, which was in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) but was discontinued after the Phase 3 CYPRESS study did not meet its primary endpoint.

Theravance Biopharma operates through its U.S. and Europe geographical segments. YUPELRI has also received regulatory approval in China, with Viatris Inc. responsible for its development and commercialization in that market.

Theravance Biopharma's brand reputation is centered on its commitment to developing "Medicines that Make a Difference®" and its focus on organ-selective medicines for serious diseases, emphasizing its expertise in FDA-approved YUPELRI for COPD. The failure of the Ampreloxetine Phase 3 CYPRESS study and subsequent program termination may negatively affect its reputation, but the continued strong performance of YUPELRI and commitment to financial discipline may mitigate these challenges.

Theravance Biopharma has significant institutional ownership, with 173 institutional owners holding a total of 49,604,382 shares as of April 10, 2026. Major institutional shareholders include Madison Avenue Partners, LP, Weiss Asset Management LP, Newtyn Management, LLC, BlackRock, Inc., Irenic Capital Management LP, and Vanguard Group Inc. Top individual insider shareholders as of March 23, 2026, include Eli Samaha, Rick E. Winningham, and Frank Pasqualone.